Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus

NCT02533570 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

20

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision based on portfolio prioritization

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: Brentuximab vedotin
DRUG: Placebo

Sponsor

Seagen Inc.